Yan-Yang Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yan-Yang Wang has a total of 123 co-authors. Here are the top co-authors by number of shared publications:
Ren Zhao
Department of Radiation Oncology, General Hospital of Ningxia Medical University, Yinchuan, China
16 shared publications- Hong Zhe
Department of Radiation Oncology, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China
8 shared publications Rong Ma
Department of Radiation Oncology, General Hospital of Ningxia Medical University, Yinchuan, China
6 shared publications- Ren Zhao
Department of Radiation Oncology, General Hospital of Ningxia Medical University, Yinchuan, Ningxia 750004, China
5 shared publications Cui-Ying Zhang
Department of Radiation Oncology, General Hospital of Ningxia Medical University, Yinchuan, 750004 Ningxia, China
4 shared publicationsHong Zhe
Department of Radiation Oncology, General Hospital of Ningxia Medical UniversityYinchuan 750004, Ningxia, China; Cancer Institute, Ningxia Medical UniversityYinchuan 750004, Ningxia, China
4 shared publications
Latest Publications
- Open Access
- 30 July 2026
- Published by Springer Nature in Nano-Micro Letters
- Vol. 19 (1) , 9
Biomimetic PD-1-Functionalized Immunostimulatory Nanomedicine Enables STING Activation and Durable Antitumor Immunity in Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) responds poorly to immune checkpoint blockade, largely because of an immunologically cold tumor microenvironment (TME) characterized by deficient antigen presentation and impaired cytotoxic T cell responses. Analysis of numerous HCC clinical cohorts, including our institutional datasets, reveals that stimulator of interferon genes (STING) pathway activity is positively correlated with patient survival, enhanced antigen presentation capacity, and an immune-activated TME. However, achieving effective and controllable STING activation in immune-cold HCC tumors remains challenging. Here, we develop a biomimetic nanomedicine that integrates photothermal therapy (PTT), STING pathway activation, and immune checkpoint blockade to treat refractory HCC. A coordination nanomedicine MCI-NP is engineered by co-encapsulating the STING agonist MSA-2 and indocyanine green (ICG) via Cu 2+ -mediated chelation, enabling stabilized PTT-induced immunogenic cell death together with robust STING-driven innate immune activation. Further cloaked with PD-1-overexpressing cell membranes, MCI-NP@mPD-1 achieves an approximately fivefold increase in tumor accumulation compared with uncoated MCI-NP and enables localized PD-1/PD-L1 axis blockade. Following a single treatment, MCI-NP@mPD-1-based photothermal immunotherapy effectively suppresses primary tumor growth and significantly prolongs survival by remodeling the TME toward an immune-active state, while inducing durable systemic immune memory that effectively limited postoperative lung metastasis. Without introducing additional nanocarriers or excipients, MCI-NP@mPD-1 offers a promising therapeutic paradigm for photothermal immunotherapy of immune-cold HCC.
- 30 July 2026
- Published by Springer Nature in Nano-Micro Letters
- Vol. 19 (1) , 9
Open AccessBiomimetic PD-1-Functionalized Immunostimulatory Nanomedicine Enables STING Activation and Durable Antitumor Immunity in Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) responds poorly to immune checkpoint blockade, largely because of an immunologically cold tumor microenvironment (TME) characterized by deficient antigen presentation and impaired cytotoxic T cell responses. Analysis of numerous HCC clinical cohorts, including our institutional datasets, reveals that stimulator of interferon genes (STING) pathway activity is positively correlated with patient survival, enhanced antigen presentation capacity, and an immune-activated TME. However, achieving effective and controllable STING activation in immune-cold HCC tumors remains challenging. Here, we develop a biomimetic nanomedicine that integrates photothermal therapy (PTT), STING pathway activation, and immune checkpoint blockade to treat refractory HCC. A coordination nanomedicine MCI-NP is engineered by co-encapsulating the STING agonist MSA-2 and indocyanine green (ICG) via Cu 2+ -mediated chelation, enabling stabilized PTT-induced immunogenic cell death together with robust STING-driven innate immune activation. Further cloaked with PD-1-overexpressing cell membranes, MCI-NP@mPD-1 achieves an approximately fivefold increase in tumor accumulation compared with uncoated MCI-NP and enables localized PD-1/PD-L1 axis blockade. Following a single treatment, MCI-NP@mPD-1-based photothermal immunotherapy effectively suppresses primary tumor growth and significantly prolongs survival by remodeling the TME toward an immune-active state, while inducing durable systemic immune memory that effectively limited postoperative lung metastasis. Without introducing additional nanocarriers or excipients, MCI-NP@mPD-1 offers a promising therapeutic paradigm for photothermal immunotherapy of immune-cold HCC.
- Open Access
- 1 October 2025
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 14 (10) , 6588-6604
Bioinformatics analysis identifies ULK3 as a novel prognostic and immune-related biomarker in esophageal cancer
Background: Esophageal cancer (EC) is a leading global malignancy, exhibiting high incidence in East Asia, especially China. Although tumor, node, metastasis (TNM) staging remains the cornerstone of clinical evaluation, molecular profiling of tumors and blood now offers complementary prognostic and therapeutic information. Yet patient survival rates remain unsatisfactory. Autophagy plays a dual role in tumor. ULK3, a kinase related to autophagy regulation, remains underexplored in EC. This study aimed to investigate the role of ULK3 in EC prognosis and tumor immunity. Methods: ULK3 expression patterns were examined across pan-cancer and EC using The University of ALabama at Birmingham CANcer data analysis Portal (UALCAN) and Gene Expression Profiling Interactive Analysis (GEPIA2), with gene set cancer analysis (GSCA) characterizing its single nucleotide variation (SNV) and copy number variation (CNV) profiles. Gene Expression Omnibus (GEO) datasets validated these findings [GSE13898: esophageal adenocarcinoma (EAC), 15 Barrett’s esophagus, 28 normal; GSE53625: 179 esophageal squamous cell carcinoma (ESCC), 179 normal; GSE77861: 7 ESCC, 7 normal; GSE92396: 12 EAC, 9 normal; GSE213565: 10 ESCC, 10 normal]. GEPIA2 and KM-Plotter assessed prognostic associations with EC and immunotherapy patients, which were subsequently validated in GSE53625, while GSCA analyzed CNV-survival correlations. The Cancer Genome Atlas (TCGA) EC cohort (96 ESCC, 88 EAC, 1 mucinous cystic neoplasm), incorporating race, tumor location, pathological grade, smoking status, alcohol consumption, gender, age, stage, molecular markers, and overall survival (OS) was used to analyze ULK3’s clinical associations and prognostic value. Immune infiltration, T-cell exhaustion, and immunotherapy response were evaluated using TCGA EC, complemented by GSCA’s drug sensitivity assessment. Pathway enrichment analysis was used to explore potential mechanisms, while T-cell and epithelial phenotypes across ULK3 expression groups were compared using single-cell RNA sequencing (SCRNA-seq) data (GSE196756: 3 ESCC, 3 normal). Mendelian randomization (MR) employed data from FinnGen and IEU OPEN Genome-Wide Association Study (GWAS) to investigate genetic susceptibility of ULK3 and EC. Results: ULK3 expression was elevated in normal EC tissues, with pan-cancer SNV mutations primarily consisting of missense mutations and EC CNV mutations biased toward deletions. Multivariate Cox regression identified ULK3 as an independent survival factor [hazard ratio (HR): 0.417, 95% confidence interval (CI): 0.218–0.798, P=0.008]. Immunologically, ULK3 was associated with reduced macrophage infiltration, improved chemotherapy and immunotherapy responses. Enrichment analysis showed ULK3 association with epidermal growth, immune regulation, and microautophagy pathways. ScRNA-seq data revealed ULK3-mediated T-cell activation and suppression of tumor phenotype. MR analysis yielded consistent risk associations [IEU OPEN GWAS, odds ratio (OR): 0.9994, 95% CI: 0.9992–0.9996, P=7.89×10−8; FinnGen, OR: 0.9047, 95% CI: 0.8218–0.9959, P=0.04]. Conclusions: ULK3’s mutation profile, expression patterns, prognostic associations, immune correlations and MR results suggest that its elevated expression may reduce EC risk and progression, supporting its potential as a prognostic biomarker. Single-cell and pathway analyses indicate that microautophagy-mediated regulation of tumor proliferation and immunity underlies these effects.
- 1 October 2025
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 14 (10) , 6588-6604
Open AccessBioinformatics analysis identifies ULK3 as a novel prognostic and immune-related biomarker in esophageal cancer
Background: Esophageal cancer (EC) is a leading global malignancy, exhibiting high incidence in East Asia, especially China. Although tumor, node, metastasis (TNM) staging remains the cornerstone of clinical evaluation, molecular profiling of tumors and blood now offers complementary prognostic and therapeutic information. Yet patient survival rates remain unsatisfactory. Autophagy plays a dual role in tumor. ULK3, a kinase related to autophagy regulation, remains underexplored in EC. This study aimed to investigate the role of ULK3 in EC prognosis and tumor immunity. Methods: ULK3 expression patterns were examined across pan-cancer and EC using The University of ALabama at Birmingham CANcer data analysis Portal (UALCAN) and Gene Expression Profiling Interactive Analysis (GEPIA2), with gene set cancer analysis (GSCA) characterizing its single nucleotide variation (SNV) and copy number variation (CNV) profiles. Gene Expression Omnibus (GEO) datasets validated these findings [GSE13898: esophageal adenocarcinoma (EAC), 15 Barrett’s esophagus, 28 normal; GSE53625: 179 esophageal squamous cell carcinoma (ESCC), 179 normal; GSE77861: 7 ESCC, 7 normal; GSE92396: 12 EAC, 9 normal; GSE213565: 10 ESCC, 10 normal]. GEPIA2 and KM-Plotter assessed prognostic associations with EC and immunotherapy patients, which were subsequently validated in GSE53625, while GSCA analyzed CNV-survival correlations. The Cancer Genome Atlas (TCGA) EC cohort (96 ESCC, 88 EAC, 1 mucinous cystic neoplasm), incorporating race, tumor location, pathological grade, smoking status, alcohol consumption, gender, age, stage, molecular markers, and overall survival (OS) was used to analyze ULK3’s clinical associations and prognostic value. Immune infiltration, T-cell exhaustion, and immunotherapy response were evaluated using TCGA EC, complemented by GSCA’s drug sensitivity assessment. Pathway enrichment analysis was used to explore potential mechanisms, while T-cell and epithelial phenotypes across ULK3 expression groups were compared using single-cell RNA sequencing (SCRNA-seq) data (GSE196756: 3 ESCC, 3 normal). Mendelian randomization (MR) employed data from FinnGen and IEU OPEN Genome-Wide Association Study (GWAS) to investigate genetic susceptibility of ULK3 and EC. Results: ULK3 expression was elevated in normal EC tissues, with pan-cancer SNV mutations primarily consisting of missense mutations and EC CNV mutations biased toward deletions. Multivariate Cox regression identified ULK3 as an independent survival factor [hazard ratio (HR): 0.417, 95% confidence interval (CI): 0.218–0.798, P=0.008]. Immunologically, ULK3 was associated with reduced macrophage infiltration, improved chemotherapy and immunotherapy responses. Enrichment analysis showed ULK3 association with epidermal growth, immune regulation, and microautophagy pathways. ScRNA-seq data revealed ULK3-mediated T-cell activation and suppression of tumor phenotype. MR analysis yielded consistent risk associations [IEU OPEN GWAS, odds ratio (OR): 0.9994, 95% CI: 0.9992–0.9996, P=7.89×10−8; FinnGen, OR: 0.9047, 95% CI: 0.8218–0.9959, P=0.04]. Conclusions: ULK3’s mutation profile, expression patterns, prognostic associations, immune correlations and MR results suggest that its elevated expression may reduce EC risk and progression, supporting its potential as a prognostic biomarker. Single-cell and pathway analyses indicate that microautophagy-mediated regulation of tumor proliferation and immunity underlies these effects.
- 9 August 2024
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 210
Clinical Factors Influencing the Radiation Dose of Circulating Immune Cells during Radiotherapy for Small Cell Lung Cancer
Small cell lung cancer (SCLC) has garnered significant attention due to its high malignancy, propensity for distant metastasis, and poor prognosis. ... Jove
- 9 August 2024
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 210
Clinical Factors Influencing the Radiation Dose of Circulating Immune Cells during Radiotherapy for Small Cell Lung Cancer
Small cell lung cancer (SCLC) has garnered significant attention due to its high malignancy, propensity for distant metastasis, and poor prognosis. ... Jove
- Open Access
- 6 August 2024
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1439209
Bibliometric analysis of bone metastases from lung cancer research from 2004 to 2023
Background: Bone metastases of lung cancer (BMLC) severely diminish patients’ quality of life due to bone-related events, and the lack of clear guidelines globally regarding medical and surgical treatment significantly reduces patient survival. While knowledge about BMLC has grown exponentially over the past two decades, a comprehensive and objective bibliometric analysis remains absent.Methods: A comprehensive bibliometric analysis was conducted on relevant literature on BMLC extracted from the Web of Science database from 2004 to 2023 by Biblioshiny, VOSviewer, Scimago Graphica, CiteSpace, and Microsoft Office Excel Professional Plus 2016 software. 936 papers related to BMLC were extracted from the Web of Science Core Collection (WoSCC). The number of publications, countries, institutions, global collaborations, authors, journals, keywords, thematic trends, and cited references were then visualized. Finally, the research status and development direction in the last 20 years were analyzed.Results: This study included a total of 936 papers on BMLC from 2004 to 2023. There has been a steady increase in global publications each year, peaking in 2021. China had the highest number of publications, followed by Japan and the United States. Additionally, China had the most citations with an H-index of 35, while the US followed with an H-index of 34, highlighting their significant contributions to the field. “Frontiers in Oncology” had the highest number of publications. CiteSpace analysis identified “lung cancer,” “bone metastasis,” and “survival” as the top high-frequency keywords, encapsulating the core research focus. Keyword clustering analysis revealed six main clusters representing the primary research directions. Burst analysis of keywords showed that “skeletal complications” had the highest burst intensity from 2005 to 2013, while recent research trends include “immunotherapy” and “denosumab,” with bursts from 2021 to 2023. Trend topic analysis indicated that “non-small cell lung cancer,” “immunotherapy,” and “immune checkpoint inhibitors” represent the cutting-edge research directions in this field.Conclusion: This article reveals the current status and trend of research on BMLC, which is increasing worldwide. China and the United States have contributed the most, but international cooperative research on BMLC should be strengthened. The pathogenesis, early prevention, and individualized treatment of BMLC need to be strengthened for further study, and immunotherapy is the next hotspot of lung cancer bone metastasis research.
- 6 August 2024
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1439209
Open AccessBibliometric analysis of bone metastases from lung cancer research from 2004 to 2023
Background: Bone metastases of lung cancer (BMLC) severely diminish patients’ quality of life due to bone-related events, and the lack of clear guidelines globally regarding medical and surgical treatment significantly reduces patient survival. While knowledge about BMLC has grown exponentially over the past two decades, a comprehensive and objective bibliometric analysis remains absent.Methods: A comprehensive bibliometric analysis was conducted on relevant literature on BMLC extracted from the Web of Science database from 2004 to 2023 by Biblioshiny, VOSviewer, Scimago Graphica, CiteSpace, and Microsoft Office Excel Professional Plus 2016 software. 936 papers related to BMLC were extracted from the Web of Science Core Collection (WoSCC). The number of publications, countries, institutions, global collaborations, authors, journals, keywords, thematic trends, and cited references were then visualized. Finally, the research status and development direction in the last 20 years were analyzed.Results: This study included a total of 936 papers on BMLC from 2004 to 2023. There has been a steady increase in global publications each year, peaking in 2021. China had the highest number of publications, followed by Japan and the United States. Additionally, China had the most citations with an H-index of 35, while the US followed with an H-index of 34, highlighting their significant contributions to the field. “Frontiers in Oncology” had the highest number of publications. CiteSpace analysis identified “lung cancer,” “bone metastasis,” and “survival” as the top high-frequency keywords, encapsulating the core research focus. Keyword clustering analysis revealed six main clusters representing the primary research directions. Burst analysis of keywords showed that “skeletal complications” had the highest burst intensity from 2005 to 2013, while recent research trends include “immunotherapy” and “denosumab,” with bursts from 2021 to 2023. Trend topic analysis indicated that “non-small cell lung cancer,” “immunotherapy,” and “immune checkpoint inhibitors” represent the cutting-edge research directions in this field.Conclusion: This article reveals the current status and trend of research on BMLC, which is increasing worldwide. China and the United States have contributed the most, but international cooperative research on BMLC should be strengthened. The pathogenesis, early prevention, and individualized treatment of BMLC need to be strengthened for further study, and immunotherapy is the next hotspot of lung cancer bone metastasis research.
- Open Access
- 17 June 2024
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 24 (1) , 1-9
The role of transforming growth factor-β (TGF-β) in the formation of exhausted CD8 + T cells
CD8 + T cells exert a critical role in eliminating cancers and chronic infections, and can provide long-term protective immunity. However, under the exposure of persistent antigen, CD8 + T cells can differentiate into terminally exhausted CD8 + T cells and lose the ability of immune surveillance and disease clearance. New insights into the molecular mechanisms of T-cell exhaustion suggest that it is a potential way to improve the efficacy of immunotherapy by restoring the function of exhausted CD8 + T cells. Transforming growth factor-β (TGF-β) is an important executor of immune homeostasis and tolerance, inhibiting the expansion and function of many components of the immune system. Recent studies have shown that TGF-β is one of the drivers for the development of exhausted CD8 + T cells. In this review, we summarized the role and mechanisms of TGF-β in the formation of exhausted CD8 + T cells and discussed ways to target those to ultimately enhance the efficacy of immunotherapy.
- 17 June 2024
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 24 (1) , 1-9
Open AccessThe role of transforming growth factor-β (TGF-β) in the formation of exhausted CD8 + T cells
CD8 + T cells exert a critical role in eliminating cancers and chronic infections, and can provide long-term protective immunity. However, under the exposure of persistent antigen, CD8 + T cells can differentiate into terminally exhausted CD8 + T cells and lose the ability of immune surveillance and disease clearance. New insights into the molecular mechanisms of T-cell exhaustion suggest that it is a potential way to improve the efficacy of immunotherapy by restoring the function of exhausted CD8 + T cells. Transforming growth factor-β (TGF-β) is an important executor of immune homeostasis and tolerance, inhibiting the expansion and function of many components of the immune system. Recent studies have shown that TGF-β is one of the drivers for the development of exhausted CD8 + T cells. In this review, we summarized the role and mechanisms of TGF-β in the formation of exhausted CD8 + T cells and discussed ways to target those to ultimately enhance the efficacy of immunotherapy.
- Open Access
- 11 July 2023
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 21 (1) , 1-8
Prognostic factors in patients with thymoma who underwent surgery
Purpose: Thymoma is the most common primary tumor in the anterior mediastinum. The prognostic factors of patients with thymoma still need to be clarified. In this study, we aimed to investigate the prognostic factors of patients with thymoma who received radical resection and establish the nomogram to predict the prognosis of these patients. Materials and methods: Patients who underwent radical resection for thymoma with complete follow-up data between 2005 and 2021 were enrolled. Their clinicopathological characteristics and treatment methods were retrospectively analyzed. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method and compared by the log-rank test. Univariate and multivariate Cox proportional hazards regression analyses were performed to identify the independent prognostic factors. According to the results of the univariate analysis in the Cox regression model, the predictive nomograms were created. Results: A total of 137 patients with thymoma were enrolled. With a median follow-up of 52 months, the 5-year and 10-year PFS rates were 79.5% and 68.1%, respectively. The 5-year and 10-year OS rates were 88.4% and 73.1%, respectively. Smoking status (P = 0.022) and tumor size (P = 0.039) were identified as independent prognostic factors for PFS. Multivariate analysis showed that a high level of neutrophils (P = 0.040) was independently associated with OS. The nomogram showed that the World Health Organization (WHO) histological classification contributed more to the risk of recurrence than other factors. Neutrophil count was the most important predictor of OS in patients with thymoma. Conclusion: Smoking status and tumor size are risk factors for PFS in patients with thymoma. A high level of neutrophils is an independent prognostic factor for OS. The nomograms developed in this study accurately predict PFS and OS rates at 5 and 10 years in patients with thymoma based on individual characteristics.
- 11 July 2023
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 21 (1) , 1-8
Open AccessPrognostic factors in patients with thymoma who underwent surgery
Purpose: Thymoma is the most common primary tumor in the anterior mediastinum. The prognostic factors of patients with thymoma still need to be clarified. In this study, we aimed to investigate the prognostic factors of patients with thymoma who received radical resection and establish the nomogram to predict the prognosis of these patients. Materials and methods: Patients who underwent radical resection for thymoma with complete follow-up data between 2005 and 2021 were enrolled. Their clinicopathological characteristics and treatment methods were retrospectively analyzed. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method and compared by the log-rank test. Univariate and multivariate Cox proportional hazards regression analyses were performed to identify the independent prognostic factors. According to the results of the univariate analysis in the Cox regression model, the predictive nomograms were created. Results: A total of 137 patients with thymoma were enrolled. With a median follow-up of 52 months, the 5-year and 10-year PFS rates were 79.5% and 68.1%, respectively. The 5-year and 10-year OS rates were 88.4% and 73.1%, respectively. Smoking status (P = 0.022) and tumor size (P = 0.039) were identified as independent prognostic factors for PFS. Multivariate analysis showed that a high level of neutrophils (P = 0.040) was independently associated with OS. The nomogram showed that the World Health Organization (WHO) histological classification contributed more to the risk of recurrence than other factors. Neutrophil count was the most important predictor of OS in patients with thymoma. Conclusion: Smoking status and tumor size are risk factors for PFS in patients with thymoma. A high level of neutrophils is an independent prognostic factor for OS. The nomograms developed in this study accurately predict PFS and OS rates at 5 and 10 years in patients with thymoma based on individual characteristics.
- Open Access
- 5 January 2023
- Published by Wiley in Journal of Oncology
- Vol. 2023, 1-11
Silencing UBQLN2 Enhances the Radiosensitivity of Esophageal Squamous Cell Carcinoma (ESCC) via Activating p38 MAPK
Background. Ubiquilin 2 (UBQLN2) is an adaptor of ubiquitinated proteins and the proteasome. The potential role of UBQLN2 in carcinogenesis has been demonstrated. However, its role in modulating the radiosensitivity of cancer is not clear. Here, we explored the radiosensitizing effect of silencing UBQLN2 on esophageal squamous cell carcinoma (ESCC) and its mechanisms. Methods. We analyzed the prognostic role of UBQLN2 in the ESCC patient cohort from the Cancer Genomic Atlas (TCGA) database and our hospital. We also conducted a series of experiments in vivo and in vitro to investigate the effect of silencing UBQLN2 on ESCC radiosensitivity and its mechanisms. Results. UBQLN2 is highly expressed in ESCC tissues and positively correlated with poor overall survival (OS). The knockdown of UBQLN2 dramatically increased the radiosensitivity of ESCC cells. Mechanically, UBQLN2 suppression substantially upregulated p38 mitogen-activated protein kinases (MAPK). The p38 MAPK inhibitor SB203580 could reverse the radiation-enhancing effect induced by UBQLN2 knockdown. The direct interaction between UBQLN2 and p38 MAPK was confirmed by co-immunoprecipitation (CO-IP) assay. Furthermore, silencing UBQLN2 also inhibited the expression of phosphorylated DNA-dependent protein kinase catalytic subunit (p-DNA-PKcs) after irradiation. Finally, the xenografted tumor experiment confirmed the radiosensitizing effect of silencing UBQLN2 on ESCC in vivo. Conclusion. Our results suggest that silencing UBQLN2 enhances the radiosensitivity of ESCC by activating p38 MAPK, and UBQLN2 may be a potential target to enhance the radiosensitivity of ESCC.
- 5 January 2023
- Published by Wiley in Journal of Oncology
- Vol. 2023, 1-11
Open AccessSilencing UBQLN2 Enhances the Radiosensitivity of Esophageal Squamous Cell Carcinoma (ESCC) via Activating p38 MAPK
Background. Ubiquilin 2 (UBQLN2) is an adaptor of ubiquitinated proteins and the proteasome. The potential role of UBQLN2 in carcinogenesis has been demonstrated. However, its role in modulating the radiosensitivity of cancer is not clear. Here, we explored the radiosensitizing effect of silencing UBQLN2 on esophageal squamous cell carcinoma (ESCC) and its mechanisms. Methods. We analyzed the prognostic role of UBQLN2 in the ESCC patient cohort from the Cancer Genomic Atlas (TCGA) database and our hospital. We also conducted a series of experiments in vivo and in vitro to investigate the effect of silencing UBQLN2 on ESCC radiosensitivity and its mechanisms. Results. UBQLN2 is highly expressed in ESCC tissues and positively correlated with poor overall survival (OS). The knockdown of UBQLN2 dramatically increased the radiosensitivity of ESCC cells. Mechanically, UBQLN2 suppression substantially upregulated p38 mitogen-activated protein kinases (MAPK). The p38 MAPK inhibitor SB203580 could reverse the radiation-enhancing effect induced by UBQLN2 knockdown. The direct interaction between UBQLN2 and p38 MAPK was confirmed by co-immunoprecipitation (CO-IP) assay. Furthermore, silencing UBQLN2 also inhibited the expression of phosphorylated DNA-dependent protein kinase catalytic subunit (p-DNA-PKcs) after irradiation. Finally, the xenografted tumor experiment confirmed the radiosensitizing effect of silencing UBQLN2 on ESCC in vivo. Conclusion. Our results suggest that silencing UBQLN2 enhances the radiosensitivity of ESCC by activating p38 MAPK, and UBQLN2 may be a potential target to enhance the radiosensitivity of ESCC.
- Open Access
- 26 October 2022
- Published by Springer Nature in Experimental Hematology & Oncology
- Vol. 11 (1) , 1-4
Recall of reactive cutaneous capillary endothelial proliferation (RCCEP) induced by stereotactic body radiation therapy (SBRT) in a patient with lung squamous cell carcinoma
Camrelizumab (SHR-1210) is a humanized IgG4 monoclonal anti-programmed cell death protein 1 (PD-1) antibody that has been shown to inhibit the binding of PD-1 to PD-L1, thereby blocking the immune escape of various types of cancer, including lung squamous cell carcinoma (LSCC). Reactive cutaneous capillary endothelial proliferation (RCCEP) is the most common adverse event in camrelizumab-treated patients. Here, we introduce a case of LSCC with recall RCCEP induced by stereotactic body radiation therapy (SBRT). A 76-year-old LSCC patient developed RCCEP when he received camrelizumab and chemotherapy. After discontinuing camrelizumab treatment, the RCCEP lesions spontaneously regressed and fell off. However, when the patient received subsequent SBRT, the RCCEP occurred again at the same sites. This case may provide clues for additional study of the immune reactivation effect of SBRT or the underlying mechanism of RCCEP.
- 26 October 2022
- Published by Springer Nature in Experimental Hematology & Oncology
- Vol. 11 (1) , 1-4
Open AccessRecall of reactive cutaneous capillary endothelial proliferation (RCCEP) induced by stereotactic body radiation therapy (SBRT) in a patient with lung squamous cell carcinoma
Camrelizumab (SHR-1210) is a humanized IgG4 monoclonal anti-programmed cell death protein 1 (PD-1) antibody that has been shown to inhibit the binding of PD-1 to PD-L1, thereby blocking the immune escape of various types of cancer, including lung squamous cell carcinoma (LSCC). Reactive cutaneous capillary endothelial proliferation (RCCEP) is the most common adverse event in camrelizumab-treated patients. Here, we introduce a case of LSCC with recall RCCEP induced by stereotactic body radiation therapy (SBRT). A 76-year-old LSCC patient developed RCCEP when he received camrelizumab and chemotherapy. After discontinuing camrelizumab treatment, the RCCEP lesions spontaneously regressed and fell off. However, when the patient received subsequent SBRT, the RCCEP occurred again at the same sites. This case may provide clues for additional study of the immune reactivation effect of SBRT or the underlying mechanism of RCCEP.
- 23 June 2022
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 43 (9) , 1026-1033
Integrated 18F-FDG PET/CT parameter defines metabolic oligometastatic non-small cell lung cancer
Aims: The purpose of this study was to define metabolic oligometastatic non-small cell lung cancer (NSCLC) by using the number of metastatic lesions and 18F-FDG PET/CT parameters. Methods: One hundred twenty-four newly diagnosed stage IV NSCLC patients who received pretreatment 18F-FDG PET/CT examination were retrospectively analyzed. The maximum standardized uptake value (SUVmax) of primary and metastatic lesions and the collected clinical parameters were fed into the univariate and multivariate Cox proportional hazard model. Survival analysis was performed using Kaplan–Meier and log-rank test. Results: In univariate analysis, the results revealed that histology, metastatic organ numbers, adrenal gland metastasis, SUVmax of both primary and metastatic lesions, lactate dehydrogenase, systemic treatment, and local treatment were significantly correlated with overall survival of stage IV NSCLC patients. Multivariate analysis demonstrated that SUVmax of primary lesions and systemic treatment were independent risk factors of stage IV NSCLC patients. The addition of primary lung cancer SUVmax to traditional method (only count the numbers of metastasis lesions) enhanced the identification of oligometastatic NSCLC and the C-index increased from 0.601 to 0.693. Conclusion: We developed a method for the definition of metabolic oligometastatic NSCLC, which combined the number of organs involved, the number of metastatic lesions, and the SUVmax of primary lung cancer.
- 23 June 2022
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 43 (9) , 1026-1033
Integrated 18F-FDG PET/CT parameter defines metabolic oligometastatic non-small cell lung cancer
Aims: The purpose of this study was to define metabolic oligometastatic non-small cell lung cancer (NSCLC) by using the number of metastatic lesions and 18F-FDG PET/CT parameters. Methods: One hundred twenty-four newly diagnosed stage IV NSCLC patients who received pretreatment 18F-FDG PET/CT examination were retrospectively analyzed. The maximum standardized uptake value (SUVmax) of primary and metastatic lesions and the collected clinical parameters were fed into the univariate and multivariate Cox proportional hazard model. Survival analysis was performed using Kaplan–Meier and log-rank test. Results: In univariate analysis, the results revealed that histology, metastatic organ numbers, adrenal gland metastasis, SUVmax of both primary and metastatic lesions, lactate dehydrogenase, systemic treatment, and local treatment were significantly correlated with overall survival of stage IV NSCLC patients. Multivariate analysis demonstrated that SUVmax of primary lesions and systemic treatment were independent risk factors of stage IV NSCLC patients. The addition of primary lung cancer SUVmax to traditional method (only count the numbers of metastasis lesions) enhanced the identification of oligometastatic NSCLC and the C-index increased from 0.601 to 0.693. Conclusion: We developed a method for the definition of metabolic oligometastatic NSCLC, which combined the number of organs involved, the number of metastatic lesions, and the SUVmax of primary lung cancer.
- Open Access
- 27 February 2022
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 20 (1) , 1-8
Clinical characteristics and patient outcomes of molecular subtypes of small cell lung cancer (SCLC)
Background: Recent studies have shown that according to the expression levels of achaete-scute homolog 1 (ASCL1), neurogenic differentiation factor 1 (NEUROD1), and POU class 2 homeobox 3 (POU2F3), small cell lung cancer (SCLC) can be divided into four subtypes: SCLC-A (ASCL1-dominant), SCLC-N (NEUROD1-dominant), SCLC-P (POU2F3-dominant), and SCLC-I (triple negative or SCLC-inflamed). However, there are limited data on the clinical characteristics and prognosis of molecular subtypes of SCLC. Methods: Immunohistochemistry (IHC) was used to detect the expression levels of ASCL1, NEUROD1, and POU2F3 in 53 patient samples of resectable SCLC. The subtype was defined by the differential expression of the transcription factors for ASCL1, NEUROD1, and POU2F3 or the low expression of all three factors with an inflamed gene signature (SCLC-A, SCLC-N, SCLC-P, and SCLC-I, respectively). The clinicopathological characteristics, immunological features (programmed death ligand 1 [PD-L1] expression and CD8+ tumor infiltrating lymphocyte [TIL] density), and patient outcomes of the four subtypes of SCLC were analyzed. Results: Positive ASCL1, NEUROD1, and POU2F3 staining was detected in 43 (79.2%), 27 (51.0%), and 17 (32.1%) SCLC specimens by IHC. According to the results of IHC analysis, SCLC was divided into four subtypes: SCLC-A (39.6%), SCLC-N (28.3%), SCLC-P (17.0%), and SCLC-I (15.1%). The 5-year overall survival (OS) rates of these four subtypes were 61.9%, 69.3%, 41.7%, and 85.7%, respectively (P=0.251). There were significant differences in smoking status among different subtypes of SCLC (P= 0.031). However, we did not confirm the correlation between subtypes of SCLC and other clinicopathological factors or immune profiles. Cox multivariate analysis showed that N stage (P=0.025), CD8+ TILs (P=0.024), Ki-67 level (P=0.040), and SCLC-P (P=0.023) were independent prognostic factors for resectable SCLC. Conclusions: Our IHC-based study validated the proposed classification of SCLC using the expression patterns of key transcriptional regulatory factors. We found that SCLC-P was associated with smokers and was one of the poor prognostic factors of limited-stage SCLC. In addition, no correlation was found between PD-L1 expression or CD8+ TIL density and SCLC subtypes.
- 27 February 2022
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 20 (1) , 1-8
Open AccessClinical characteristics and patient outcomes of molecular subtypes of small cell lung cancer (SCLC)
Background: Recent studies have shown that according to the expression levels of achaete-scute homolog 1 (ASCL1), neurogenic differentiation factor 1 (NEUROD1), and POU class 2 homeobox 3 (POU2F3), small cell lung cancer (SCLC) can be divided into four subtypes: SCLC-A (ASCL1-dominant), SCLC-N (NEUROD1-dominant), SCLC-P (POU2F3-dominant), and SCLC-I (triple negative or SCLC-inflamed). However, there are limited data on the clinical characteristics and prognosis of molecular subtypes of SCLC. Methods: Immunohistochemistry (IHC) was used to detect the expression levels of ASCL1, NEUROD1, and POU2F3 in 53 patient samples of resectable SCLC. The subtype was defined by the differential expression of the transcription factors for ASCL1, NEUROD1, and POU2F3 or the low expression of all three factors with an inflamed gene signature (SCLC-A, SCLC-N, SCLC-P, and SCLC-I, respectively). The clinicopathological characteristics, immunological features (programmed death ligand 1 [PD-L1] expression and CD8+ tumor infiltrating lymphocyte [TIL] density), and patient outcomes of the four subtypes of SCLC were analyzed. Results: Positive ASCL1, NEUROD1, and POU2F3 staining was detected in 43 (79.2%), 27 (51.0%), and 17 (32.1%) SCLC specimens by IHC. According to the results of IHC analysis, SCLC was divided into four subtypes: SCLC-A (39.6%), SCLC-N (28.3%), SCLC-P (17.0%), and SCLC-I (15.1%). The 5-year overall survival (OS) rates of these four subtypes were 61.9%, 69.3%, 41.7%, and 85.7%, respectively (P=0.251). There were significant differences in smoking status among different subtypes of SCLC (P= 0.031). However, we did not confirm the correlation between subtypes of SCLC and other clinicopathological factors or immune profiles. Cox multivariate analysis showed that N stage (P=0.025), CD8+ TILs (P=0.024), Ki-67 level (P=0.040), and SCLC-P (P=0.023) were independent prognostic factors for resectable SCLC. Conclusions: Our IHC-based study validated the proposed classification of SCLC using the expression patterns of key transcriptional regulatory factors. We found that SCLC-P was associated with smokers and was one of the poor prognostic factors of limited-stage SCLC. In addition, no correlation was found between PD-L1 expression or CD8+ TIL density and SCLC subtypes.